Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study
Inflammatory Bowel Diseases · 13.11.2026
DOI: 10.1093/ibd/izag222 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 13.11.2026. Verfasst von Alexandre Nuzzo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, IBD, and Nutritional Support, Center for Intestinal Failure, Reference Centre for Rare Disease MarDI, AP-HP, Beaujon …. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
In corticosteroid-resistant acute severe ulcerative colitis (ASUC), cyclosporine is frequently used in biologic-exposed patients, but data on maintenance strategies after cyclosporine response remain limited. We aimed to describe 12-month outcomes after a cyclosporine-to-biologic bridge and to explore outcomes according to maintenance therapy.
Methods
This single-center retrospective study screened all patients treated with cyclosporine for ASUC between 2014 and 2024. Patients who responded to cyclosporine and subsequently received vedolizumab or ustekinumab as maintenance therapy were included. The primary endpoint was 12-month colectomy-free survival. Secondary endpoints included steroid-free clinical remission, combined clinical/biological remission, treatment persistence, and adverse events. Comparisons between maintenance therapies were exploratory.
Results
Among 67 patients treated with cyclosporine for ASUC, 44 responders were included (35 vedolizumab, 9 ustekinumab, and 96% biologic-exposed). Median follow-up was 39 months. Maintenance therapy was initiated a median of 7 days after cyclosporine initiation. Overall 12-month colectomy-free survival was 73% (95% CI, 61-88). In exploratory analyses, colectomy-free survival appeared lower with ustekinumab than with vedolizumab (47% vs 79%, log-rank P = .03). At 12 months, overall treatment persistence was 46% and combined clinical/biological remission was 34%. Adverse events were predominantly renal or neurological.
Conclusions
In this predominantly biologic-exposed, cyclosporine-responsive ASUC cohort, a bridge to vedolizumab or ustekinumab was associated with 73% colectomy-free survival at 12 months and an acceptable safety profile. Comparisons between maintenance therapies remain exploratory.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, IBD, and Nutritional Support, Center for Intestinal Failure, Reference Centre for Rare Disease MarDI, AP-HP, Beaujon Hospital, Clichy, France.
- Laboratory for Vascular Translational Science, INSERM 1148, Université Paris Cité, Paris, France.
- Paris IBD Center, Groupe Hospitalier Prive Ambroise Pare Hartmann, Neuilly sur Seine, France.
- Department of Colorectal Surgery, AP-HP, Beaujon Hospital, Clichy, France.
- Centre de Recherche sur l'Inflammation, INSERM 1149, Université Paris Cité, Paris, France.
- UVSQ/Université Paris Saclay, Infection & Inflammation, INSERM 1173, Montigny-le-Bretonneux, France.
ORCID-Profile: Alexandre Nuzzo, Thomas Bazin
Zitieren
APA
Nuzzo, A., Harb, M., Stefanescu, C., Berea, T., Bouhnik, Y., Treton, X., Ribeiro, L., Joly, F., & Bazin, T. (2026). Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag222
Vancouver
Nuzzo A, Harb M, Stefanescu C, Berea T, Bouhnik Y, Treton X, et al. Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag222
BibTeX
@article{Nuzzo2026,
author = {Nuzzo, Alexandre and Harb, Marc and Stefanescu, Carmen and Berea, Teodor and Bouhnik, Yoram and Treton, Xavier and Ribeiro, Lara and Joly, Francisca and Bazin, Thomas},
title = {Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag222}
}
EUVIMED